{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:13:42Z","timestamp":1784772822762,"version":"3.55.0"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Starting in 2014, US guidelines have not recommended \u03b2-blockers for first-line treatment of hypertension in the absence of compelling indications due to their tolerability profile and inferior protection against stroke and mortality compared with other first-line agents. The prevalence and factors associated with this guideline-discordant practice are unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the prevalence of and factors associated with first-line \u03b2-blocker use among those without compelling indications for a \u03b2-blocker.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Serial cross-sectional study of new users of antihypertensive medications using national, patient-level data in the Veterans Health Administration between January 1, 2000, and December 31, 2022. Patients were veterans initiating antihypertensive medications for newly diagnosed hypertension in the outpatient setting based on diagnosis codes and prescription dispenses, excluding veterans without a primary care visit in the prior year.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Initiation of antihypertensive medications for newly diagnosed hypertension.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Among those without compelling indications (ie, aortic aneurysm and\/or disease, angina, atrial fibrillation or arrhythmia, chronic liver disease or cirrhosis, heart failure with reduced ejection fraction, myocardial infarction, or coronary revascularization), multivariable Poisson regression was used to estimate factors associated with \u03b2-blocker initiation.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 3\u202f138\u202f304 included veterans (mean [SD] age 61.0 [13.0] years, 2\u202f958\u202f488 [94.3%] male, 149\u202f807 [4.8%] Hispanic, 490\u202f636 [15.6%] non-Hispanic Black, 2\u202f028\u202f127 [64.6%] non-Hispanic White, and and 66\u202f798 [2.1%] other races and ethnicities ), 774\u202f821 (24.7%) initiated a \u03b2-blocker. Overall, 684\u202f045 patients (88.2%) who initiated a \u03b2-blocker did not have compelling indications, which decreased over time from 245\u202f703 (91.8%) in 2000 through 2005 to 93\u202f088 (81.5%) in 2018 to 2022. Metoprolol and carvedilol were the most commonly initiated \u03b2-blockers and increased over time, and atenolol initiation decreased over time. Among other factors, a greater prevalence ratio for \u03b2-blocker initiation was observed among older (PR, 1.05; 95% CI, 1.04-1.05), female (PR, 1.11; 95% CI, 1.09-1.14), non-Hispanic White (as reference group; Non-Hispanic Black PR, 0.74; 95% CI, 0.73-0.76; Hispanic PR, 0.75; 95% CI, 0.73-0.77; all others PR, 0.89; 95% CI, 0.86-0.92) or frail veterans (PR, 1.28; 95% CI, 1.25-1.31).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, most veterans using \u03b2-blockers as a first-line treatment for hypertension did not have compelling indications, and several factors were associated with likelihood of \u03b2-blocker initiation in this group. Interventions are needed to improve initial guideline-concordant treatment for veterans with incident hypertension.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.29026","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:31:04Z","timestamp":1756308664000},"page":"e2529026","source":"Crossref","is-referenced-by-count":1,"title":["First-Line \u03b2-Blocker Use for Hypertension in the Veterans Health Administration"],"prefix":"10.1001","volume":"8","author":[{"given":"Catherine G.","family":"Derington","sequence":"first","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransmond O.","family":"Berchie","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April F.","family":"Mohanty","sequence":"additional","affiliation":[{"name":"George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah"},{"name":"Department of Internal Medicine, Spencer Fox-Eccles School of Medicine, Division of Epidemiology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhe","family":"Xu","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"},{"name":"Department of Internal Medicine, Spencer Fox-Eccles School of Medicine, Division of Epidemiology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan B.","family":"King","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"},{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Rethy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Zickmund","sequence":"additional","affiliation":[{"name":"George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah"},{"name":"Department of Internal Medicine, Spencer Fox-Eccles School of Medicine, Division of Epidemiology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Michael","family":"Ho","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"},{"name":"Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"},{"name":"Colorado Permanente Medical Group, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"},{"name":"Veterans Affairs Eastern Colorado Health System, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Medicine, Renal-Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City"},{"name":"George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"19","key":"zoi250817r1","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"zoi250817r2","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"issue":"6555","key":"zoi250817r3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care.","volume":"293","author":"Coope","year":"1986","journal-title":"BMJ (Clin Res Ed)"},{"issue":"8778","key":"zoi250817r4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).","volume":"338","author":"Dahl\u00f6f","year":"1991","journal-title":"Lancet"},{"issue":"24","key":"zoi250817r5","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"issue":"5","key":"zoi250817r6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"zoi250817r7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials.","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"issue":"19","key":"zoi250817r8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"zoi250817r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis.","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7705","key":"zoi250817r10","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"zoi250817r11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. head-to-head comparisons of various classes of antihypertensive drugs\u2014overview and meta-analyses.","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"issue":"9489","key":"zoi250817r12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"issue":"9311","key":"zoi250817r13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"19","key":"zoi250817r14","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNa guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"zoi250817r15","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 Guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association.","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"issue":"6","key":"zoi250817r16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/HJH.0000000000003733","article-title":"For debate: the 2023 European Society of Hypertension guidelines - cause for concern.","volume":"42","author":"Shantsila","year":"2024","journal-title":"J Hypertens"},{"issue":"33","key":"zoi250817r17","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"zoi250817r18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"20","key":"zoi250817r22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036557","volume":"13","author":"Xu","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"7624","key":"zoi250817r23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"19","key":"zoi250817r24","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi250817r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108714","article-title":"The association of opioid use disorder and homelessness nationally in the veterans health administration.","volume":"223","author":"Manhapra","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi250817r26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.ajkd.2010.08.031","article-title":"Validity of administrative database coding for kidney disease: a systematic review.","volume":"57","author":"Vlasschaert","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"zoi250817r27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1053\/j.ajkd.2014.07.012","article-title":"Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.","volume":"65","author":"Muntner","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"zoi250817r28","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"zoi250817r29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1472-6963-6-161","article-title":"ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction.","volume":"6","author":"So","year":"2006","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"zoi250817r30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12913-019-4574-3","article-title":"Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review.","volume":"19","author":"Gothe","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"zoi250817r31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study.","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"zoi250817r32","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glab071","author":"Cheng","year":"2021","journal-title":"J Gerontol: Series A"},{"key":"zoi250817r33","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly232","author":"Orkaby","year":"2019","journal-title":"J Gerontol: Series A"},{"issue":"4","key":"zoi250817r34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","article-title":"Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.","volume":"7","author":"Kumamaru","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"zoi250817r35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.109.139279","article-title":"Validation of a case definition to define hypertension using administrative data.","volume":"54","author":"Quan","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"zoi250817r36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/gerona\/gly134","article-title":"Cross-sectional association of frailty and arterial stiffness in community-dwelling older adults: the framingham heart study.","volume":"74","author":"Orkaby","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"zoi250817r37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study.","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi250817r38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits.","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"zoi250817r40","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension guidelines.","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"zoi250817r41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12931-024-02964-2","article-title":"CT-based whole lung radiomics nomogram for identification of PRISm from non-COPD subjects.","volume":"25","author":"Zhou","year":"2024","journal-title":"Respir Res"},{"issue":"1","key":"zoi250817r42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0587.2012.07348.x","article-title":"Collinearity: a review of methods to deal with it and a simulation study evaluating their performance.","volume":"36","author":"Dormann","year":"2013","journal-title":"Ecography"},{"issue":"10","key":"zoi250817r43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.rec.2019.04.014","article-title":"Role of beta-blockers in cardiovascular disease in 2019.","volume":"72","author":"Mart\u00ednez-Milla","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"zoi250817r44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.amjhyper.2005.09.009","author":"Weber","year":"2005","journal-title":"American J Hypertension"},{"issue":"21","key":"zoi250817r45","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation \u00df-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"issue":"9446","key":"zoi250817r46","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"9496","key":"zoi250817r47","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"issue":"6488","key":"zoi250817r48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results.","volume":"291","author":"Medical Research Council Working Party","year":"1985","journal-title":"BMJ (Clin Res Ed)"},{"issue":"6824","key":"zoi250817r49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results.","volume":"304","author":"MRC Working Party","year":"1992","journal-title":"BMJ"},{"issue":"10022","key":"zoi250817r50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"zoi250817r51","first-page":"351","article-title":"Beta-blockers and the treatment of hypertension: it is time to move on.","volume":"18","author":"Wiysonge","year":"2007","journal-title":"Cardiovasc J Afr"},{"issue":"2","key":"zoi250817r52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1751-7176.2008.08021.x","article-title":"Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.","volume":"10","author":"Sarafidis","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"zoi250817r53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-6175.2005.04089.x","article-title":"Analysis of recent papers in hypertension.","volume":"7","author":"Basile","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"18","key":"zoi250817r54","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"22","key":"zoi250817r55","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.","volume":"344","author":"Eichhorn","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250817r56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"zoi250817r57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejim.2023.12.015","article-title":"Rationale of treatment recommendations in the 2023 ESH hypertension guidelines.","volume":"121","author":"Mancia","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"16","key":"zoi250817r58","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s11606-022-07612-3","article-title":"National trends in antihypertensive treatment among older adults by race and presence of comorbidity, 2008 to 2017.","volume":"37","author":"Anderson","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi250817r59","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026652","article-title":"Initial antihypertensive regimens in newly treated patients: real world evidence from the OneFlorida+ clinical research network.","volume":"12","author":"Smith","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"zoi250817r60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25127","article-title":"Association of race\/ethnicity-specific changes in antihypertensive medication classes initiated among Medicare beneficiaries with the Eighth Joint National Committee panel member report.","volume":"3","author":"Colvin","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi250817r61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/pds.2041","article-title":"Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data.","volume":"20","author":"Garg","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi250817r19","unstructured":"Department of Veterans Administration. VA\/DoD clinical practice guideline management for the diagnosis and management of hypertension in the primary care setting\u2014version 2.0. 2004. Accessed January 4, 2024. https:\/\/www.healthquality.va.gov\/hypertension\/htn04_pdf1.pdf"},{"key":"zoi250817r20","unstructured":"Department of Veterans Affairs. VA\/DoD clinical practice guideline management for the diagnosis and management of hypertension in the primary care setting\u2014version 3.0. 2014. Accessed January 4, 2024. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/htn\/VADoDCPGfortheManagementofHTN.pdf"},{"key":"zoi250817r21","unstructured":"Department of Veterans Affairs. VA\/DoD clinical practice guideline management for the diagnosis and management of hypertension in the primary care setting\u2014version 4.0. 2020. Accessed January 4, 2024. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/htn\/VADoDHypertensionCPG508Corrected792020.pdf"},{"key":"zoi250817r39","unstructured":"US Department of Veterans Affairs. Veterans Benefits Administration\u2014regional offices. February 4, 2020. Accessed March 12, 2020. https:\/\/www.benefits.va.gov\/benefits\/offices.asp"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838076\/derington_2025_oi_250817_1755634461.84308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:31:10Z","timestamp":1756308670000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29026","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}